Abeona Therapeutics Inc. (NASDAQ:ABEO - Free Report) - Investment analysts at HC Wainwright upped their FY2026 earnings per share estimates for shares of Abeona Therapeutics in a research note issued to investors on Thursday, November 12th. HC Wainwright analyst R. Selvaraju now anticipates that the biopharmaceutical company will earn ($0.96) per share for the year, up from their previous estimate of ($1.15). HC Wainwright has a "Buy" rating on the stock. The consensus estimate for Abeona Therapeutics' current full-year earnings is ($0.97) per share. HC Wainwright also issued estimates for Abeona Therapeutics' Q4 2026 earnings at ($0.22) EPS, Q1 2027 earnings at ($0.24) EPS, Q2 2027 earnings at ($0.22) EPS, Q3 2027 earnings at ($0.20) EPS, Q4 2027 earnings at ($0.17) EPS and FY2027 earnings at ($0.82) EPS.
Several other brokerages also recently commented on ABEO. Wall Street Zen upgraded Abeona Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday. Weiss Ratings cut Abeona Therapeutics from a "sell (d)" rating to a "sell (d-)" rating in a report on Tuesday, November 10th. Oppenheimer reaffirmed an "outperform" rating and issued a $21.00 price objective (down from $22.00) on shares of Abeona Therapeutics in a research report on Friday, August 14th. UBS Group reiterated a "buy" rating on shares of Abeona Therapeutics in a research note on Friday, September 25th. Finally, Cantor Fitzgerald boosted their target price on shares of Abeona Therapeutics from $28.00 to $30.00 and gave the stock an "overweight" rating in a research report on Friday, September 18th. Five equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Abeona Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $21.00.
Read Our Latest Analysis on ABEO
Abeona Therapeutics Price Performance
Shares of NASDAQ ABEO opened at $2.42 on Monday. Abeona Therapeutics has a 1-year low of $2.09 and a 1-year high of $7.65. The company has a market capitalization of $138.30 million, a price-to-earnings ratio of -2.26 and a beta of 1.50. The business has a 50-day moving average of $4.70 and a 200-day moving average of $5.39.
Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) last issued its quarterly earnings data on Monday, November 9th. The biopharmaceutical company reported ($0.08) EPS for the quarter, topping analysts' consensus estimates of ($0.17) by $0.09. Abeona Therapeutics had a negative return on equity of 44.82% and a negative net margin of 160.30%. The company had revenue of $13.49 million for the quarter, compared to analysts' expectations of $14.82 million.
Insider Activity at Abeona Therapeutics
In other news, CFO Joseph Vazzano sold 9,191 shares of Abeona Therapeutics stock in a transaction dated Tuesday, September 29th. The stock was sold at an average price of $5.16, for a total transaction of $47,425.56. Following the sale, the chief financial officer directly owned 482,888 shares of the company's stock, valued at approximately $2,491,702.08. The trade was a 1.87% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, SVP Brendan O'Malley sold 6,727 shares of the business's stock in a transaction dated Tuesday, September 29th. The stock was sold at an average price of $5.16, for a total value of $34,711.32. Following the completion of the transaction, the senior vice president owned 421,226 shares in the company, valued at approximately $2,173,526.16. This trade represents a 1.57% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders sold 55,428 shares of company stock valued at $296,508. 7.10% of the stock is currently owned by insiders.
Institutional Investors Weigh In On Abeona Therapeutics
Hedge funds and other institutional investors have recently bought and sold shares of the business. Global Retirement Partners LLC boosted its stake in shares of Abeona Therapeutics by 1,026.2% during the 3rd quarter. Global Retirement Partners LLC now owns 4,978 shares of the biopharmaceutical company's stock valued at $26,000 after buying an additional 4,536 shares during the last quarter. Royal Bank of Canada grew its position in shares of Abeona Therapeutics by 49.6% during the first quarter. Royal Bank of Canada now owns 6,500 shares of the biopharmaceutical company's stock worth $29,000 after buying an additional 2,155 shares in the last quarter. Dimensional Fund Advisors LP acquired a new stake in shares of Abeona Therapeutics during the first quarter worth approximately $154,000. WINTON GROUP Ltd bought a new stake in shares of Abeona Therapeutics in the second quarter worth $256,000. Finally, Rangeley Capital LLC increased its stake in shares of Abeona Therapeutics by 4.2% in the first quarter. Rangeley Capital LLC now owns 60,000 shares of the biopharmaceutical company's stock worth $269,000 after buying an additional 2,400 shares during the last quarter. 80.56% of the stock is currently owned by hedge funds and other institutional investors.
Key Abeona Therapeutics News
These are some of the ABEO news items that stood out recently:
- Positive Sentiment: HC Wainwright raised its FY2026 EPS estimate to a loss of $0.96 from a loss of $1.15, and its Q4 2026 estimate to a loss of $0.22 from $0.24. The firm reiterated its Buy rating. MarketBeat analyst estimates
- Neutral Sentiment: Wall Street Zen raised its rating on ABEO to Hold, a less cautious stance that nevertheless does not signal a Buy recommendation. Abeona Therapeutics Stock Bumped Up to Hold by Wall Street Zen
- Negative Sentiment: HC Wainwright cut its FY2027 EPS estimate to a loss of $0.82 from $0.49 and lowered its estimates for each quarter of 2027, signaling expectations of greater losses than previously forecast. MarketBeat analyst estimates
Abeona Therapeutics Company Profile
(
Get Free Report)
Abeona Therapeutics, Inc. is a biotechnology company focused on developing cell and gene therapies for serious and rare diseases. Its work includes treatments designed to address the underlying genetic causes of disease. The company's lead product, ZEVASKYN (prademagene zamikeracel), is an autologous gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa, a rare inherited skin disorder. Made from a patient's skin cells, the therapy uses genetic modification to help cells produce type VII collagen and is applied to wounds.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Abeona Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abeona Therapeutics wasn't on the list.
While Abeona Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.